Pharmacological BET inhibition has shown significant efficacy against MLL FP leukemias in vitro and in vivo by inducing cell-cycle arrest and apoptosis [219], but also against NPM1c-mutant leukemias [220]. The gene discussed is KMT2A; the disease is leukemia.